Abstract
Background
Alkaline phosphatase (ALP) has been implicated to be associated with poor outcome in ischemic stroke patients, yet its role in aneurysmal subarachnoid hemorrhage (aSAH) patients is unknown. The current study aimed to investigate the on-admission and short-term variation trend of ALP levels in aSAH patients as well as its associations with vasospasm, delayed cerebral ischemia (DCI), and outcome after aSAH.
Methods
Between January 2014 and May 2018, all consecutive aSAH patients were prospectively enrolled. Blood samples from patients and 78 healthy individuals were obtained. Baseline information, clinical data, and radiologic data were collected, and serum ALP levels during hospitalization were measured. Patients were followed up for 6 months.
Results
One hundred and ninety-six aSAH patients were included. The serum ALP levels in aSAH patients were significantly higher compared to controls (71 vs. 61 U/L, p = 0.0002), yet did not differ significantly between patients with severe (WFNS 4–5) and mild clinical condition (72 vs. 63 U/L, p = 0.3362). However, ALP was significantly higher in patients with severe radiologic status (modified Fisher 3–4) compared to those with mild radiologic status (77 vs. 61.5 U/L, p = 0.0005). A significant correlation emerged between modified Fisher score and ALP level (r = 0.246, p = 0.001). Multivariable analysis found that higher ALP level was associated with angiographic vasospasm (OR 1.019, 95% CI 1.002–1.036, p = 0.026) and DCI-caused clinical deterioration (OR 1.019, 95% CI 1.001–1.037, p = 0.037), while higher WFNS score, modified Fisher score, and ALP level were independently associated with unfavorable outcome (serum ALP level, OR 1.083, 95% CI 1.041–1.127, p < 0.001). Trend analysis of ALP level based on 103 patients’ data revealed a significant decrease in ALP level on post-admission day 7–9 (median; on-admission day vs. post-admission day 7–9, 72 vs. 60 U/L, p = 0.0012; post-admission day 3–5 vs. day 7–9, 70 vs. 60 U/L, p = 0.0052) and subsequent increase in ALP level on post-admission day 12–14 (median, 84 U/L, p < 0.0001). Higher ALP levels were observed in patients with unfavorable outcome on on-admission day, post-admission day 3–5, and 12–14 (median; unfavorable vs. favorable; on-admission day, 86 vs. 67 U/L, p = 0.0122; post-admission day 3–5, 80 vs. 64 U/L, p = 0.0044; post-admission day 7–9, 75 vs. 53.5 U/L, p < 0.0001) but not on post-admission day 12–14.
Conclusions
Elevated serum ALP level is associated with vasospasm, DCI-caused clinical deterioration, and functional outcome after aSAH. Further studies are required to examine the potential role of serum ALP as an outcome predictor for aSAH patients.
This is a preview of subscription content,
to check access.



References
Lawton MT, Vates GE. Subarachnoid hemorrhage. N Engl J Med. 2017;377:257–66.
Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The international cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg. 1990;73:18–36.
Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164:1199–209.
Perticone F, Perticone M, Maio R, et al. Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in naive hypertensive patients. Hypertension. 2015;66:874–80.
Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH. Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. Arterioscler Thromb Vasc Biol. 2013;33:1070–6.
Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120:1784–92.
Shimizu Y, Imano H, Ohira T, et al. Alkaline phosphatase and risk of stroke among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Stroke Cerebrovasc Dis. 2013;22:1046–55.
Abramowitz M, Muntner P, Coco M, et al. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol. 2010;5:1064–71.
Park JB, Kang DY, Yang HM, et al. Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. Eur Heart J. 2013;34:920–31.
Zong L, Wang X, Li Z, et al. Alkaline phosphatase and outcomes in patients with preserved renal function: results from China National Stroke Registry. Stroke. 2018;49:1176–82.
Zhong C, You S, Chen J, et al. Serum alkaline phosphatase, phosphate, and in-hospital mortality in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2018;27:257–66.
Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Increased serum alkaline phosphatase as a predictor of long-term mortality after stroke. Neurology. 2010;75:1995–2002.
Liu J, Wang D, Li J, et al. Increased serum alkaline phosphatase as a predictor of symptomatic hemorrhagic transformation in ischemic stroke patients with atrial fibrillation and/or rheumatic heart disease. J Stroke Cerebrovasc Dis. 2016;25:2448–52.
Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1711–37.
Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211–40.
Schumann GKR, Canalias F, Bossert-Reuther S, Franck PF, Gella FJ. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37°C. Part 9: reference procedure for the measurement of catalytic concentration of alkaline phosphatase International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division, Committee on Reference Systems of Enzymes (C-RSE) (1). Clin Chem Lab Med. 2011;49:1439–46.
Drake CG. Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68:985–6.
Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1–9.
Vergouwen MD. Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. Neurocrit Care. 2011;15:308–11.
Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391–5.
Saver JL, Filip B, Hamilton S, et al. Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA). Stroke. 2010;41:992–5.
Tan G, Hao Z, Lei C, et al. Subclinical change of liver function could also provide a clue on prognosis for patients with spontaneous intracerebral hemorrhage. Neurol Sci. 2016;37:1693–700.
Bannister RG, Romanul FC. The localization of alkaline phosphatase activity in cerebral blood vessels. J Neurol Neurosurg Psychiatry. 1963;26:333–40.
Lee HB, Kim J, Kim SH, Kim S, Kim OJ, Oh SH. Association between serum alkaline phosphatase level and cerebral small vessel disease. PLoS ONE. 2015;10:e0143355.
Arun P, Oguntayo S, Albert SV, et al. Acute decrease in alkaline phosphatase after brain injury: a potential mechanism for tauopathy. Neurosci Lett. 2015;609:152–8.
Diaz-Hernandez M, Hernandez F, Miras-Portugal MT, Avila J. TNAP plays a key role in neural differentiation as well as in neurodegenerative disorders. Subcell Biochem. 2015;76:375–85.
Kermer V, Ritter M, Albuquerque B, Leib C, Stanke M, Zimmermann H. Knockdown of tissue nonspecific alkaline phosphatase impairs neural stem cell proliferation and differentiation. Neurosci Lett. 2010;485:208–11.
Webber M, Krishnan A, Thomas NG, Cheung BM. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005–2006. Clin Chem Lab Med. 2010;48:167–73.
Adler Y, Fink N, Spector D, Wiser I, Sagie A. Mitral annulus calcification—a window to diffuse atherosclerosis of the vascular system. Atherosclerosis. 2001;155:1–8.
Ryu WS, Lee SH, Kim CK, Kim BJ, Kwon HM, Yoon BW. High serum alkaline phosphatase in relation to cerebral small vessel disease. Atherosclerosis. 2014;232:313–8.
Provencio JJ, Fu X, Siu A, Rasmussen PA, Hazen SL, Ransohoff RM. CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage. Neurocrit Care. 2010;12:244–51.
Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg. 2003;99:376–82.
Miller BA, Turan N, Chau M, Pradilla G. Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage. Biomed Res Int. 2014;2014:384342.
Provencio JJ. Inflammation in subarachnoid hemorrhage and delayed deterioration associated with vasospasm: a review. Acta Neurochir Suppl. 2013;115:233–8.
Schutte R, Huisman HW, Malan L, et al. Alkaline phosphatase and arterial structure and function in hypertensive African men: the SABPA study. Int J Cardiol. 2013;167:1995–2001.
Faust K, Horn P, Schneider UC, Vajkoczy P. Blood pressure changes after aneurysmal subarachnoid hemorrhage and their relationship to cerebral vasospasm and clinical outcome. Clin Neurol Neurosurg. 2014;125:36–40.
Acknowledgments
The authors thank all stuff in Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, for their technical support. This study was supported by the National Nature Science Foundation of China (Nos. 81701208 and 81371371), Key Research and Development Plan of Zhejiang Province (No. 2019C03095), and Medicine and Health Technology Plan of Zhejiang Province (No. 2019KY396).
Funding
None.
Author information
Authors and Affiliations
Contributions
YZ: project development, data collection and management, data analysis, manuscript writing. HJ: data collection and management, manuscript writing. YL: data collection and management, manuscript writing. YW: data collection and management. KX: data collection and management. LZ: data collection and management. HL: data collection and management. TS: data collection. DC: data management. JS: data collection and management. JZ: data management. DY: data management. DW: data management. RZ: project development, manuscript writing and editing.
Corresponding author
Ethics declarations
Conflicts of Interest
All authors declare that there are no competing interests with regard to publication of this paper.
Ethical Approval/Informed Consent
This study was approved by the Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine. Informed consent was obtained from study population or family members in all cases.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure 1
ROC curve analysis of serum ALP level for identifying patients with 6-month unfavorable outcome. The AUC was calculated based on the ROC curves and expressed as 95% CI. AUC ranges from 0.5 to 1.0. An AUC closer to 1 indicates a higher predictive power. (TIFF 100 kb)
Rights and permissions
About this article
Cite this article
Zhu, Y., Jiang, H., Li, Y. et al. Serum Alkaline Phosphatase Level is Associated with Angiographic Vasospasm, Delayed Cerebral Ischemia-Caused Clinical Deterioration, and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care 31, 466–475 (2019). https://doi.org/10.1007/s12028-019-00714-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-019-00714-7